Northwest Biotherapeutics (NWBO) Target Lifted to $15.10 at Summer Street
Tweet
Share
E-mailGet Alerts NWBO Hot Sheet
Price: $0.19 --0%
Rating Summary:
1 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
1 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Summer Street analyst Carol Werther reiterated a Buy rating and raised her price target on Northwest Biotherapeutics (NASDAQ: NWBO) from $10.33 to $15.10 earlier, following news yesterday Germany has approved DCVax-L, a glioblastoma multiforme (GBM) vaccine, for an early access program.
"This is very strong endorsement from the German government," Werther said.
For an analyst ratings summary and ratings history on Northwest Biotherapeutics click here. For more ratings news on Northwest Biotherapeutics click here.
Shares of Northwest Biotherapeutics closed at $7.85 yesterday.
"This is very strong endorsement from the German government," Werther said.
For an analyst ratings summary and ratings history on Northwest Biotherapeutics click here. For more ratings news on Northwest Biotherapeutics click here.
Shares of Northwest Biotherapeutics closed at $7.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
- DA Davidson Reiterates Neutral Rating on Timken (TKR)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
